PwPepwise

Dulaglutide

Weight Loss

a.k.a. Trulicity

Weekly GLP-1 agonist

Dulaglutide is a once-weekly injectable medication belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class.

§Dosing at a glance

8 protocols · from the research
What it's forDoseHow oftenHowFor how long
Standard Adult Dosing (Type 2 Diabetes)0.75 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.—
Starting dose0.75 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.—
Standard therapeutic dose1.5 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.—
Higher doses3.0 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.—
Japan-specific dosing0.75 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.—
Combination Therapy Protocols1.5 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.24 wks
Pediatric Dosing (Youth with Type 2 Diabetes)0.75 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.10–17 yrs
heart-related Outcome Trial Protocol1.5 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.—

Approximate values pulled from the research — double-check before dosing.

§01Summary

Dulaglutide is a once-weekly injectable medication belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class, approved for the treatment of type 2 diabetes in adults and, more recently, in youth. It works by mimicking a natural gut hormone that stimulates insulin release, suppresses glucagon, slows stomach emptying, and reduces appetite — all in a glucose-dependent manner that significantly limits the risk of dangerous low blood sugar episodes.

The evidence base for dulaglutide is extensive. It reduces blood sugar (HbA1c) significantly compared to placebo and performs comparably or superiorly to other major diabetes medications including metformin12, sitagliptin5, exenatide4, and insulin glargine7. A landmark cardiovascular outcomes trial demonstrated that dulaglutide reduces the risk of major cardiovascular events — including heart attack, stroke, and cardiovascular death — in a broad population of people with type 2 diabetes1. It also reduces the risk of kidney disease progression, particularly the development of protein in the urine2, and may support cognitive health over the long term13. Dulaglutide produces modest but meaningful weight loss alongside glycemic control5,7, and its once-weekly dosing schedule offers a practical convenience advantage over daily injectable or oral alternatives3.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Dulaglutide is a long-acting GLP-1 receptor agonist consisting of two identical GLP-1(7-37) analog chains, each covalently linked via a small peptide spacer to a modified human IgG4 Fc fragment. This fusion protein architecture confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage and renal filtration, yielding a plasma half-life of approximately 4–5 days that supports once-weekly subcutaneous dosing1,3. The GLP-1 analog sequence incorporates amino acid substitutions at positions 8 (Ala→Gly) and 34 (Lys→Arg) to prevent DPP-4-mediated N-terminal cleavage and to eliminate GIP receptor cross-reactivity, respectively, while the Fc modification (L234A/L235A/P331S) abrogates Fc receptor binding and complement activation to minimize immunologic consequences.

Dulaglutide exerts its primary metabolic effects through agonism at the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed on pancreatic beta cells, alpha cells, the gastrointestinal tract, the central nervous system, the heart, the kidneys, and vascular endothelium. GLP-1R activation on beta cells stimulates adenylyl cyclase via Gαs coupling, elevating intracellular cAMP and activating protein kinase A (PKA) and EPAC2 pathways, which potentiate glucose-stimulated insulin secretion in a strictly glucose-dependent manner — mechanistically explaining the low intrinsic hypoglycemia risk observed consistently across trials4,5,12. Simultaneous GLP-1R activation on pancreatic alpha cells suppresses postprandial glucagon secretion, reducing hepatic glucose output. Activation of hypothalamic and brainstem GLP-1R pathways reduces appetite and food intake, contributing to the weight reduction observed across clinical trials5,7,10.

The renal protective effects of dulaglutide — predominantly albuminuria reduction — are attributed to multiple potential mechanisms including GLP-1R-mediated reductions in intraglomerular pressure through afferent arteriole vasodilation, anti-inflammatory effects on the glomerular filtration barrier, and natriuresis-linked hemodynamic improvements2. The predominant effect on new macroalbuminuria (HR 0.77) over eGFR preservation suggests primarily hemodynamic and anti-inflammatory rather than structural nephroprotective mechanisms2. Cardiovascular protection, including the demonstrated reductions in MACE1 and ischemic stroke11, is likely multifactorial, involving the combination of modest systolic blood pressure reduction (~2.8 mmHg)15, direct vascular GLP-1R signaling promoting endothelial function and anti-atherosclerotic effects, and potential anti-inflammatory actions independent of glycemic improvement — evidenced by cardiovascular benefit observed even at relatively well-controlled baseline HbA1c of 7.2%1.

Following subcutaneous injection, dulaglutide undergoes slow absorption from the injection depot with peak plasma concentrations reached at approximately 48 hours. Steady-state concentrations are achieved within 2–4 weeks of once-weekly dosing. Metabolism occurs via general protein catabolism pathways (proteolytic degradation into amino acids and small peptides), with no hepatic CYP450-mediated metabolism, minimizing pharmacokinetic drug-drug interactions. The Fc fusion architecture provides the extended half-life while the modified IgG4 backbone reduces immunogenicity relative to earlier GLP-1 fusion designs3,10.

§04Evidence & efficacy

Evidence base
420Studies
210Human
9Animal

Dulaglutide demonstrates robust and well-replicated glycemic efficacy across a broad range of clinical settings and patient populations.

Glycemic Control:
Dulaglutide 1.5 mg once weekly reduces HbA1c by approximately 1.1–1.6% from baselines of approximately 8.1% across the AWARD phase 3 trials4,5,7,8,12. Both the 1.5 mg and 0.75 mg doses are superior to placebo4,12,18, superior to sitagliptin 100 mg daily5,14, superior to exenatide twice daily4, and superior to insulin glargine in a basal-bolus setting8. Dulaglutide 1.5 mg is non-inferior to once-daily liraglutide 1.8 mg for HbA1c reduction, achieving LS mean reductions of -1.42% versus -1.36%3. Higher doses of 3.0 mg and 4.5 mg provide statistically significant additional glycemic reduction versus 1.5 mg, with the 4.5 mg dose achieving LS mean HbA1c reductions of -1.77% to -1.87% from a baseline of approximately 8.6%10.

Weight Effects:
Dulaglutide produces modest but statistically significant weight reductions. In AWARD-5, dulaglutide 1.5 mg achieved weight loss of -3.03 kg versus -1.53 kg for sitagliptin at 52 weeks5. Higher doses produce greater weight reduction: -4.6 kg (4.5 mg) versus -3.0 kg (1.5 mg) at 52 weeks10. In combination with SGLT2 inhibitors, dulaglutide maintains additive glycemic benefit without meaningful increases in hypoglycemia risk6.

Cardiovascular Outcomes:
Dulaglutide 1.5 mg reduces the risk of the composite major adverse cardiovascular events (MACE) endpoint — non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death — versus placebo (HR 0.88, 95% CI 0.79–0.99; p=0.026) over a median 5.4 years in a broad type 2 diabetes population1. This cardiovascular benefit was observed in a population where approximately 69% had no prior cardiovascular event, extending the evidence beyond previously studied high-risk populations. Dulaglutide also reduces total stroke by 24% and ischemic stroke by 25% versus placebo11.

Renal Outcomes:
Dulaglutide reduces the composite renal outcome of new macroalbuminuria, sustained eGFR decline ≥30%, or chronic renal replacement therapy (HR 0.85, 95% CI 0.77–0.93; p=0.0004), with the strongest effect on new macroalbuminuria (HR 0.77, p<0.0001)2.

Cognitive Outcomes:
Dulaglutide may support cognitive health in adults with type 2 diabetes and cardiovascular risk factors, with post-hoc adjusted analyses from REWIND suggesting a 14% reduction in substantive cognitive impairment13.

Pediatric Efficacy:
In youth with type 2 diabetes, dulaglutide significantly reduces HbA1c versus placebo (-0.6 to -0.9 percentage points versus +0.6 percentage points for placebo), with 51% of dulaglutide-treated participants achieving HbA1c <7.0% versus 14% on placebo18.

Comparative Positioning:
As an active comparator, dulaglutide 1.5 mg was surpassed by tirzepatide (all doses), oral orforglipron (doses ≥12 mg), and oral semaglutide 14 mg for both glycemic control and weight loss9,17,16, positioning it as a well-established but not best-in-class agent within the evolving GLP-1 agonist landscape.

§05Safety

Dulaglutide has a well-characterized safety profile across a large body of randomized controlled trial data including over 9,900 participants in the REWIND cardiovascular outcomes trial alone1.

Gastrointestinal Adverse Events (most common):
Gastrointestinal effects are the predominant adverse events observed across all dulaglutide trials. In the REWIND trial, GI adverse events occurred in 47.4% of dulaglutide participants versus 34.1% of placebo participants1. Across the AWARD trials, nausea occurred in approximately 15–20% of patients on 1.5 mg3,7, diarrhea in 10–16%7,14, and vomiting in 7–14%3,14. These events are generally mild to moderate in severity and transient, typically occurring early in treatment. Higher doses (3.0 mg and 4.5 mg) are associated with modestly higher GI event rates in a dose-dependent manner: nausea 13.4% (1.5 mg), 15.6% (3.0 mg), 16.4% (4.5 mg)10.

Hypoglycemia:
Hypoglycemia risk is low when dulaglutide is used without concomitant insulin secretagogues or insulin, consistent with its glucose-dependent mechanism. No severe hypoglycemia was reported in AWARD-14, AWARD-312, AWARD-55, or AWARD-63 trials. When combined with insulin glargine, hypoglycemia rates were similar to placebo/glargine combination, with only one severe episode reported19. In the pediatric trial, the safety profile was consistent with the adult experience18.

Cardiovascular Effects:
Dulaglutide 1.5 mg produces a statistically significant and clinically modest reduction in 24-hour systolic blood pressure of approximately 2.8 mmHg versus placebo15. However, the 1.5 mg dose is also associated with a statistically significant increase in 24-hour heart rate of approximately 2.8 bpm that failed non-inferiority criteria, while the 0.75 mg dose was non-inferior to placebo for heart rate15. The long-term cardiovascular safety of dulaglutide is well-established through the REWIND trial, which demonstrated a net cardiovascular benefit over 5.4 years1.

Pancreatic Enzymes:
Elevations in pancreatic enzymes have been observed with dulaglutide treatment compared to insulin glargine7. No cases of clinical pancreatitis were reported in that study, though this signal warrants ongoing monitoring.

Serious Adverse Events:
In AWARD-4, serious adverse events occurred less frequently in the dulaglutide 1.5 mg group (9%) compared to insulin glargine (18%)8. In AWARD-10, serious adverse events were low and balanced across treatment groups (approximately 2–4%)6.

Pediatric Safety:
In youth with type 2 diabetes, dulaglutide's safety profile was consistent with that observed in adult populations, with no new or unexpected safety signals identified18.

§06History

The development of dulaglutide emerged from sustained research into GLP-1-based therapeutics following the seminal characterization of GLP-1's insulinotropic properties in the 1980s and the subsequent clinical validation of the GLP-1 receptor agonist class with exenatide (approved 2005) and liraglutide (approved 2010). Eli Lilly and Company pursued a long-acting molecular strategy by engineering a GLP-1 analog fused to a modified IgG4 Fc region, designed specifically to extend the half-life of native GLP-1 from under 2 minutes to approximately 4–5 days while retaining full GLP-1R agonist activity.

The pivotal phase 3 AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) clinical trial program, launched in the early 2010s, encompassed eight major trials evaluating dulaglutide across the spectrum of type 2 diabetes treatment — as monotherapy12, versus metformin12, versus sitagliptin5,14, versus exenatide4, versus liraglutide3, versus and in combination with insulin7,8,19, and in combination with SGLT2 inhibitors6. These trials collectively established dulaglutide's efficacy and safety profile, supporting regulatory approval by the U.S. FDA in September 2014 under the brand name Trulicity, followed by approvals in the European Union and other global markets.

The REWIND (Researching Cardiovascular Events with a Weekly INcretin in Diabetes) trial, reported in 2019, represented a landmark milestone by demonstrating significant cardiovascular risk reduction in a broad type 2 diabetes population1,2,11,13 — expanding both the clinical label and the therapeutic positioning of dulaglutide. Subsequent AWARD-11 data supported approval of higher doses (3.0 mg and 4.5 mg)10, and a dedicated pediatric trial established efficacy in youth18, extending the evidence base across the lifespan.

§07References